Department of Pharmaceuticals recommends export of 2000 MT in respect of Paracetamol API

The National Pharmaceutical Pricing Authority (NPPA) has allowed six major manufacturers of paracetamol active pharmaceutical ingredients (APIs) to export 2000 metric tonnes of paracetamol API. The recommendations has been issued by the Ministry of Home and Affairs.

The manufacturers mentioned below are allowed to export Paracetamol API, due to surplus availability:

Farmson Pharmaceutical -456 MT
Meghmani LLP- 209 MT
Sri Krishna Pharmaceuticals – 474 MT
Granules India- 655 MT
Bharat Chemicals- 91 MT
Para Products- 115 MT

“This is a progressive step initiated by the government by allowing the large manufacturers of paracetamol to begin the export. Since the Ministry of External Affairs is monitoring the activities of paracetamol and hydroxychloroquine (HCQ) in a licensed category and their demand position would be continuously monitored by them based on the stock position, companies would be allowed to fulfil the export commitments. The permission to export paracetamol raw materials for six large manufacturers is an encouraging step by the government. It also indicates that there will be smooth functioning of pharma exports. We look forward to permissions for other merchant exporters as well in the coming days.” Mahesh Doshi, President, Indian Drugs Manufacturers Association (IDMA) said.

B R Sikri, Chairman, Federation of Pharma Entrepreneurs (FOPE) said, “FOPE appreciates the move of the government of increasing the quantity of export of paracetamol APIs. The earlier quantity was almost 50 per cent of the current allocation, which is now 2000 metric tonnes. It shows how seriously the government is monitoring production, stock, materials in the pipeline as well as the demand-supply scenario. This is what is needed. This efficient way of working by the government will bring more such positive decisions in days to come so that neither our own people suffer for want of API or finished dosages nor the world markets which look towards India.”

  • Related Posts

    WHO launches new primary health care course to strengthen health systems globally

    Health is a human right – yet not everyone can access the health services they need, when and where they need them, without financial hardship. Primary health care (PHC) provides…

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Bengaluru: The Central Council for Research in Ayurvedic Sciences (CCRAS) has called for stronger scientific evidence, safety monitoring and translation of research into market-ready technologies to improve the credibility and…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Excellence of Accredited Hospitals to be judged on how Friendly they are with Patients

    Excellence of Accredited Hospitals to be judged on how Friendly they are with Patients

    WHO launches new primary health care course to strengthen health systems globally

    WHO launches new primary health care course to strengthen health systems globally

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A